



**DRUGS & PHARMACEUTICALS LTD.**

**MANUFACTURER OF  
BULK DRUGS &  
IMPORTERS OF  
SOLVENTS & CHEMICALS**

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ☎ : (022) 23455543 Email: [corporate@aareydrugs.com](mailto:corporate@aareydrugs.com)  
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ☎ (02525) 271049 Email: [info@aareydrugs.com](mailto:info@aareydrugs.com)  
CIN: L99999MH1990PLC056538

Date:- 13<sup>th</sup> April, 2023

To,

<b>BSE Limited</b> The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001  <b>Scrip Code: 524412</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051  <b>NSE Symbol: AAREYDRUGS</b>
--	---

**Sub:- SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018**

Dear Sir/Madam,

With reference to the captioned subject and pursuant to the circulars stated therein, we would like to confirm you that our company “Aarey Drugs & Pharmaceuticals Limited” does not fall under the definition of “Large Corporate” as on 31<sup>st</sup> March, 2023, as per the criteria specified in para 2.2 of SEBI Circular reference no. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.Hence requirement at para 4.1(i) of said circular for disclosure also does not apply to the company.

Please take on record of the same and oblige  
Thanking You,

Yours faithfully,

**For Aarey Drugs & Pharmaceuticals Limited**

**Lalit Tulsiani**  
**Director**  
**DIN: 01652630**



**MANUFACTURER OF  
BULK DRUGS &  
IMPORTERS OF  
SOLVENTS & CHEMICALS**

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ☎ : (022) 23455543 Email: [corporate@aareydrugs.com](mailto:corporate@aareydrugs.com)  
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ☎ (02525) 271049 Email: [info@aareydrugs.com](mailto:info@aareydrugs.com)  
CIN: L99999MH1990PLC056538

Annexure – XII A

Initial Disclosure to be made by an entity identified as a large corporate

Srno	Particulars	Details
1	Name of Company	Aarey Drugs and Pharmaceuticals Limited
2	CIN	L99999MH1990PLC056538
3	Outstanding borrowing of Company as on 31 <sup>st</sup> March as applicable	37.25 Cr
4	Highest Credit Rating during the previous F.Y. along with name of the Credit Rating Agency	BBB
5	Name of Stock Exchange* in which the fine shall be paid in case of shortfall in the required borro	BSE, NSE

We confirm that we are not a large Corporate as per the applicability criteria given under the Chapter XII of SEBI operational circular SEBI/HO/DDHS/ P/CIR/2021/613 dated 10<sup>th</sup> August, 2021.

**Lalit Tulsiani**  
**Director**  
**DIN: 01652630**

\*In terms of paragraph 2.2 (d) of the circular , beginning Fy 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by stock exchanges at the end of the three year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of stock exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.